Fate Therapeutics Inc (NAS:FATE)
$ 3.68 0.23 (6.67%) Market Cap: 418.90 Mil Enterprise Value: 111.25 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 58/100

Q3 2019 Fate Therapeutics Inc Earnings Call Transcript

Nov 05, 2019 / 10:00PM GMT
Release Date Price: $15.71 (+2.68%)
Operator

Welcome to the Fate Therapeutics Third Quarter 2019 Financial Results Conference Call. (Operator Instructions) This call is being webcast live on Investors and Media section of Fate's website at fatetherapeutics.com. As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, CFO, President, Treasurer, Secretary & Director

Thank you. Good afternoon and thanks, everyone, for joining us for the Fate Therapeutics Third Quarter 2019 Financial Results Call. Shortly after 4:00 PM Eastern Time today, we issued a press release with these results which can be found on the Investors & Media section of our website under Press Releases.

In addition, our Form 10-Q for the quarter ended September 30, 2019, was filed shortly thereafter and can be found on the Investors and Media section of our website under Financial Information. Before we begin, I would like to remind everyone that, except for statements of historical facts, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot